Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Thermo Fisher Scientific Inc is a diagnostics & research business based in the US. Thermo Fisher Scientific shares (TMO) are listed on the NYSE and all prices are listed in US Dollars. Thermo Fisher Scientific employs 90,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $580.33 |
|---|---|
| 52-week range | $432.65 - $672.34 |
| 50-day moving average | $635.76 |
| 200-day moving average | $552.65 |
| Wall St. target price | $691.41 |
| PE ratio | 36.7443 |
| Dividend yield | $1 (0.17%) |
| Earnings per share (TTM) | $21.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $580.33 from 2022-01-21
| 1 week (2022-01-14) | -2.43% |
|---|---|
| 1 month (2021-12-22) | -10.95% |
| 3 months (2021-10-22) | -5.17% |
| 6 months (2021-07-22) | 10.64% |
| 1 year (2021-01-22) | 12.77% |
|---|---|
| 2 years (2020-01-22) | 70.66% |
| 3 years (2019-01-22) | 141.10% |
| 5 years (2017-01-20) | 304.38% |
Valuing Thermo Fisher Scientific stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Thermo Fisher Scientific's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Thermo Fisher Scientific's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Thermo Fisher Scientific shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Thermo Fisher Scientific's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.345. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Thermo Fisher Scientific's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Thermo Fisher Scientific's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.3 billion.
The EBITDA is a measure of a Thermo Fisher Scientific's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $39.1 billion |
|---|---|
| Operating margin TTM | 27.58% |
| Gross profit TTM | $16 billion |
| Return on assets TTM | 9.78% |
| Return on equity TTM | 2428.62% |
| Profit margin | 21.93% |
| Book value | $98.24 |
| Market capitalisation | $234.4 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Thermo Fisher Scientific.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 14.69
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Thermo Fisher Scientific's overall score of 14.69 (as at 12/31/2018) is excellent – landing it in it in the 15th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Thermo Fisher Scientific is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.11/100
Thermo Fisher Scientific's environmental score of 2.11 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Thermo Fisher Scientific is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 6.69/100
Thermo Fisher Scientific's social score of 6.69 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Thermo Fisher Scientific is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 3.38/100
Thermo Fisher Scientific's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Thermo Fisher Scientific is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Thermo Fisher Scientific scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Thermo Fisher Scientific has, for the most part, managed to keep its nose clean.
Thermo Fisher Scientific Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 14.69 |
|---|---|
| Total ESG percentile | 14.7 |
| Environmental score | 2.11 |
| Environmental score percentile | 1 |
| Social score | 6.69 |
| Social score percentile | 1 |
| Governance score | 3.38 |
| Governance score percentile | 1 |
| Level of controversy | 2 |
Dividend payout ratio: 4.05% of net profits
Recently Thermo Fisher Scientific has paid out, on average, around 4.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.17% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Thermo Fisher Scientific shareholders could enjoy a 0.17% return on their shares, in the form of dividend payments. In Thermo Fisher Scientific's case, that would currently equate to about $1 per share.
While Thermo Fisher Scientific's payout ratio might seem low, this can signify that Thermo Fisher Scientific is investing more in its future growth.
Thermo Fisher Scientific's most recent dividend payout was on 13 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2021 (the "ex-dividend date").
Thermo Fisher Scientific's shares were split on a 3:2 basis on 5 June 1996. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Thermo Fisher Scientific shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Thermo Fisher Scientific shares which in turn could have impacted Thermo Fisher Scientific's share price.
Over the last 12 months, Thermo Fisher Scientific's shares have ranged in value from as little as $432.652 up to $672.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Thermo Fisher Scientific's is 0.743. This would suggest that Thermo Fisher Scientific's shares are less volatile than average (for this exchange).
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
